Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press26010.17650/1726-9776-2009-5-3-40-43PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫTHE CLINICAL AND MORPHOLOGICAL FEATURES OF LATENT PROSTATE CANCERНЕПРЕРЫВНЫЙ ЦИСТОУРЕТРОАНАСТОМОЗ ПРИ ПОЗАДИЛОННОЙ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИFedosenkoK. V.ФедосенкоК. В.
Russian Federation
fkvhome@mail.ruKarlovP. A.КарловП. А.
Russian Federation
fkvhome@mail.ruCity Clinical Cancer Dispensary, Saint PetersburgГородской клинический онкологический диспансер, Санкт-Петербург300920095340430308201403082014https://oncourology.abvpress.ru/oncur/article/view/260

The purpose of the study was to provide a retrospective clinicomorphological assessment of the results of examining 70 patients with occult prostate cancer (PC). The findings show it expedient to identify latent prostate cancer as a special clinicomorphological form having a relatively good prognosis. According to the data, surgical or medical antiandrogen blockade had not caused a significant increase in the survival time up to 9 years in these patients and the cause of death was the development of intercurrent diseases rather than tumor progression. Latent cancer is characterized by the following signs:

— detection of only single foci of malignization among a great deal of study tissue pieces) (a tumor in 1—3 out of 20—30 tissue fragments);

— a Gleason score not more than 4;

— detection of Ki-67 in more than 10% of tumor cells;

— the activity of nucleolar organizers up to 3.8;

— a strong reaction to androgen receptors in the majority of tumor cells;

— no p53 hyperexpression;

— a slight or moderate lymphoid or monocytic cell infiltration of the tissues adjacent to the tumor.

The planning of PC management should involve in-depth morphological and molecular genetic analyses.

latent prostate cancerdiagnosistreatment policyлапароскопическая позадилонная радикальная простатэктомиянепрерывный цистоуретроанастомозкатетеризация1. Humphrey P.A., Prostate Pathology. Chicago: ASCP Press, 2003.Humphrey P.A., Prostate Pathology. Chicago: ASCP Press, 2003.2. Karube K. Study of latent carcinoma of the prostate in Japanese based on necropsy material. Tohoku J Exp Med 1961;74: 265—85.Karube K. Study of latent carcinoma of the prostate in Japanese based on necropsy material. Tohoku J Exp Med 1961;74: 265—85.3. Sakr W., Permick N., Butler C. et al. The prevalence of high grade, clinically occult prostatic adenocarcinoma and its relationship to high grade PIN. Mol Pathol 2000;13:109A.Sakr W., Permick N., Butler C. et al. The prevalence of high grade, clinically occult prostatic adenocarcinoma and its relationship to high grade PIN. Mol Pathol 2000;13:109A.4. Senderoi Z., Balogh F. Der Prostatakrebs. Verlag Theodor Steinkopff. Dresden und Leipzig, 1965.Senderoi Z., Balogh F. Der Prostatakrebs. Verlag Theodor Steinkopff. Dresden und Leipzig, 1965.5. Amling C.L., Blute M.L., Lerner S.E. et al. Influence of prostate specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1996;73:401—6.Amling C.L., Blute M.L., Lerner S.E. et al. Influence of prostate specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1996;73:401—6.6. Bostwick D.G., Foster C.S. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 WHO International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17: 222—72.Bostwick D.G., Foster C.S. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 WHO International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17: 222—72.7. Buchanan G., Irvine R.A., Coetzee G.A., Tilley W.D. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20(3—4):207—23.Buchanan G., Irvine R.A., Coetzee G.A., Tilley W.D. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20(3—4):207—23.8. Epstein J.I., Paull G., Eggleston J.C. et al. Prognosis of untreated stage A1 prostatic carcinoma: study of 94 cases with extended follow-up. J Urol 1994;151:1587—92.Epstein J.I., Paull G., Eggleston J.C. et al. Prognosis of untreated stage A1 prostatic carcinoma: study of 94 cases with extended follow-up. J Urol 1994;151:1587—92.9. Hirano D., Werahera P.N., Crowford E.D. et al. Morphological analysis and classification of latent prostate cancer using 3-dementional computer algorithm: analysis of tumor volume, grade, tumor dubling time, and life expectancy. J Urol 1998;159:1265—9.Hirano D., Werahera P.N., Crowford E.D. et al. Morphological analysis and classification of latent prostate cancer using 3-dementional computer algorithm: analysis of tumor volume, grade, tumor dubling time, and life expectancy. J Urol 1998;159:1265—9.